SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist
Purpose of Review The overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination. Recent Findings Cutaneous eruptions associated with COVID-19 infection have a reported frequency of 1–20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequent vaccination. Summary Dermatologists should be aware of the associations between COVID-19 disease severity and cutaneous eruptions. Livedo racemosa and retiform purpura are particularly associated with increased disease severity and death. In the setting of COVID-19 vaccination, cutaneous eruptions can largely be managed symptomatically and very rarely do these reactions prevent subsequent vaccination..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Current dermatology reports - 11(2022), 4 vom: 19. Okt., Seite 252-262 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Himed, Sonia [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
COVID-19 cutaneous eruptions |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13671-022-00374-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR048871729 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR048871729 | ||
| 003 | DE-627 | ||
| 005 | 20230520011323.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221214s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13671-022-00374-5 |2 doi | |
| 035 | |a (DE-627)SPR048871729 | ||
| 035 | |a (SPR)s13671-022-00374-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Himed, Sonia |e verfasserin |0 (orcid)0000-0002-1553-609X |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of Review The overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination. Recent Findings Cutaneous eruptions associated with COVID-19 infection have a reported frequency of 1–20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequent vaccination. Summary Dermatologists should be aware of the associations between COVID-19 disease severity and cutaneous eruptions. Livedo racemosa and retiform purpura are particularly associated with increased disease severity and death. In the setting of COVID-19 vaccination, cutaneous eruptions can largely be managed symptomatically and very rarely do these reactions prevent subsequent vaccination. | ||
| 650 | 4 | |a COVID-19 cutaneous eruptions |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 vaccinations |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 disease severity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 vaccine reactions |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Gray, Ashley |4 aut | |
| 700 | 1 | |a Awethe, Zaynah |4 aut | |
| 700 | 1 | |a Libson, Karissa |4 aut | |
| 700 | 1 | |a Kaffenberger, Benjamin H. |4 aut | |
| 700 | 1 | |a Korman, Abraham M. |4 aut | |
| 700 | 1 | |a Trinidad, John C. L. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current dermatology reports |d New York, NY : Springer, 2012 |g 11(2022), 4 vom: 19. Okt., Seite 252-262 |w (DE-627)SPR032151217 |w (DE-600)2660493-0 |x 2162-4933 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:4 |g day:19 |g month:10 |g pages:252-262 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13671-022-00374-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 4 |b 19 |c 10 |h 252-262 | ||